Within the ecosystem networking of the cluster, restorative and regenerative medicine began by transplant technology whose growth has been marked by the development of innovative solutions, as well as alternatives to the organ shortage, and for the immunological monitoring of transplanted patients. In parallel, new therapeutic approaches have developed (biomaterials, tissue engineering, cell therapy, gene therapy) which apply to diseases of the bone and joints, dermatology, oncology, pneumology, as well as rare, neurodegenerative and cardiovascular diseases.
The structuring of this sector is carried out by “BIOREGATE” GIS (Scientific Interest Group) that brings together all of the cluster’s resources in this area, i.e. more than 40 research and care institutions, companies, technological platforms and technical facilities including GMP production centers for cells (UTCG, GBS) and viral vectors (CPV, GBS).
Several products stemming from industrial projects, which are supported by public funds (C4C, PGT, GELTOP, GAMBAS, REBORNE, CALCOMED) are currently in clinical trials, particularly gene therapy products for restoring sight to patients with very rare eye diseases such as Leber congenital amaurosis. Finally, the international visibility of those involved in the sector is ensured through several European projects (TERM, Biomat-In, NanoFar, REBORNE, GAMBAS).